SC-CAR.GPC3xIL15.21 CAR T cells

Phase 1Cell therapy

SC-CAR.GPC3xIL15.21 CAR T cells is one of 56 biologic programs targeting Solid Tumor Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor MalignanciesRecruiting

Solid TumorsNot yet recruiting

Solid Tumor MalignanciesPhase 1

Recruiting

Solid TumorsPhase 1

Not yet recruiting

Competition

Competitive Landscape

124 competitors in Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

5 2

Lynparza

AstraZeneca

Phase 3

3 3

Lenvima

Eisai

Phase 3

2 4

Taxol

Teva

Phase 2

14 5

Opdivo

Bristol-Myers Squibb

Phase 2

9 6

Imfinzi

AstraZeneca

Phase 2

6 7

Herceptin

Roche

Phase 2

5 8

Beyfortus

BeiGene

Phase 2

5 9

Fludara

Sanofi

Phase 2

3 10

Camptosar

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2044

Phase 1Recruiting

Solid Tumor Malignancies

NCT07148050

Q3 2045

Phase 1Not yet recruiting

Solid Tumors

NCT07224568

Clinical

Trials by Indication[1]

Solid Tumors1 trial

Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors

Not yet recruiting·SSeattle Children's Hospital·Phase 1·NCT07224568·21 enrolled

Solid Tumor Malignancies1 trial

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Recruiting·SSeattle Children's Hospital·Phase 1·NCT07148050·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SC-CAR.GPC3xIL15.21 CAR T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SC-CAR.GPC3xIL15.21 CAR T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SC-CAR.GPC3xIL15.21 CAR T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seattle Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: SSeattle Children's Hospital

SC-CAR.GPC3xIL15.21 CAR T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2044

Q3 2045

Trials by Indication[1]

Solid Tumors1 trial

Solid Tumor Malignancies1 trial

References

Drug Info

Quick Facts

Related News